Invention Grant
- Patent Title: Recombinant serotype 5 (Ad5) adenoviral vectors
- Patent Title (中): 重组血清型5（Ad5）腺病毒载体
-
Application No.: US14359141Application Date: 2012-11-23
-
Publication No.: US09410129B2Publication Date: 2016-08-09
- Inventor: Tuuli Ranki , Akseli Hemminki , Vincenzo Cerullo , Anniina Koski
- Applicant: Targovax Oy
- Applicant Address: FI Helsinki
- Assignee: Targovax Oy
- Current Assignee: Targovax Oy
- Current Assignee Address: FI Helsinki
- Agency: Cooley LLP
- Agent Matthew Pavao; Ivor Elrifi
- Priority: FI20116181 20111125
- International Application: PCT/FI2012/051162 WO 20121123
- International Announcement: WO2013/076374 WO 20130530
- Main IPC: C12N7/00
- IPC: C12N7/00 ; A61K45/06 ; A61K35/761
Abstract:
The invention relates to oncolytic adenovirus vectors and their uses in cancer therapy. The adenovirus vectors according to the invention have superior safety properties and have effective therapeutic activity. A production method for the inventive adenoviruses is also disclosed. The adenovirus vectors are useful in cancer therapy.
Public/Granted literature
- US20150232811A1 RECOMBINANT SEROTYPE 5 (Ad5) ADENOVIRAL VECTORS Public/Granted day:2015-08-20
Information query
